Pathogen Detection and Vaccine Candidates Contribute in Fight Against Ongoing Pandemic

Nachrichtenquelle: PR Newswire (engl.)
01.06.2020, 14:45  |  384   |   |   

- FN Media Group Presents Microsmallcap.com Market Commentary

NEW YORK, June 1, 2020 /PRNewswire/ -- As the first wave of COVID-19 begins to wane, and the second wave threatens to extend the pandemic well into the latter half of 2020, the medical community remains focused largely on two areas: detecting the virus, and treating the virus. By advancing these goals, health experts will not only be able to limit the spread of the disease, they would also be empowered to potentially end the pandemic once and for all. Though no organization can lay claim to these goals yet, among the many companies working on pathogen detection or treatment initiatives, a few stand out from the crowd for the speed, accuracy, and or broad applicability of their solutions. Through their offerings, these companies—namely, LexaGene Holdings Inc. (TSX-V:LXG) (OTCQB:LXXGF), Medmira (TSXV:MIR), Gilead Sciences, Inc. (NASDAQ:GILD), Novartis AG (NYSE:NVS), and Novavax Inc. (NASDAQ:NVAX) — can assist in reducing the impact of the novel coronavirus in terms of both economic and societal damage.

LexaGene's Open-Access, Multiplex Molecular Diagnostic Analyzer

The goal of LexaGene Holdings Inc (LXG.V) (LXXGF.QB) is to develop genetic analyzers for the rapid detection of pathogens, as well as other molecular markers. This makes it uniquely suited to deliver solutions that address COVID-19.

Beginning on January 27, long before the viral outbreak was labelled a pandemic by the World Health Organization, LexaGene addressed how its flagship offering, the LX Analyzer, can be used to detect and to ultimately help the public respond to the virus. The instrument is capable of detecting pathogens at the point-of-need in just one hour. This eliminates long wait times and the need to transport the sample from sick individuals to laboratories for manual processing.

However, the two most notable aspects of the LX Analyzer are that it is both an "open-access" and "multiplex" molecular diagnosis instrument.

Its open-access feature allows users to quickly introduce newly developed assays into the platform for fully automated and rapid detection of pathogens, even novel ones like COVID. This is how LexaGene Holdings Inc (LXG.V) (LXXGF.QB) scientists were able to detect the virus behind the current pandemic by quickly adapting the Center for Disease Control's diagnostics panel to the LX Analyzer.

Seite 1 von 6
Lexagene Holdings Aktie jetzt ab 0€ handeln - auf Smartbroker.de



Diesen Artikel teilen

Schreibe Deinen Kommentar

Bitte melden Sie sich an, um zu kommentieren. Anmelden | Registrieren

 

Disclaimer

Meistgelesene Nachrichten des Autors

Titel
Titel
Titel
Titel